SCHEMBL24574133

SCHEMBL24574133

CC(C)(C)OC(=O)N1CCCC(Nc2cccc(-c3cnc4cnc(OCC(F)F)cn34)n2)C1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ FLT3 P36888 4/20 0.47
▸ IRAK4 Q9NWZ3 9/20 0.43
▸ CCNT1 O60563 1/20 0.41
▸ TRPV3 Q8NET8 1/20 0.41
▸ FGFR3 P22607 1/20 0.41
▸ KDR P35968 1/20 0.41
▸ USP30 Q70CQ3 3/20 0.40
▸ LCK P06239 1/20 0.40
▸ RET P07949 1/20 0.40
▸ PDGFRB P09619 1/20 0.40
▸ CDK7 P50613 1/20 0.40
▸ BLK P51451 1/20 0.40
▸ IRAK1 P51617 1/20 0.40
▸ CCNH P51946 1/20 0.40
▸ SRPK1 Q96SB4 1/20 0.40
▸ PARP1 P09874 1/20 0.39
▸ GABRA5 P31644 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24574132 1.00 FLT3 (0.47) FLT3IRAK4CCNT1TRPV3FGFR3
SCHEMBL24573974 0.95 FLT3 (0.48) FLT3IRAK4CCNT1USP30LCK
SCHEMBL24574401 0.90 FLT3 (0.47) FLT3IRAK4CCNT1TRPV3USP30
SCHEMBL24574400 0.90 FLT3 (0.47) FLT3IRAK4CCNT1TRPV3USP30
SCHEMBL24573973 0.87 FLT3 (0.54) FLT3IRAK4CCNT1USP30LCK
SCHEMBL24573975 0.87 FLT3 (0.54) FLT3IRAK4CCNT1USP30LCK
SCHEMBL24574365 0.86 FLT3 (0.48) FLT3IRAK4CCNT1FGFR3KDR
SCHEMBL24574511 0.86 FLT3 (0.53) FLT3IRAK4CCNT1USP30LCK
SCHEMBL24574166 0.85 FLT3 (0.49) FLT3IRAK4CCNT1USP30LCK
SCHEMBL24573969 0.85 FLT3 (0.42) FLT3IRAK4CCNT1FGFR3KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022140647-A1 MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF CHILDREN'S HOSPITAL MEDICAL CENTER (US) 2022-06-30 — — WO disclosed
Send feedback